
Plinabulin
CAS No. 714272-27-2
Plinabulin ( NPI-2358 )
Catalog No. M15729 CAS No. 714272-27-2
Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 30 | In Stock |
![]() ![]() |
5MG | 47 | In Stock |
![]() ![]() |
10MG | 69 | In Stock |
![]() ![]() |
25MG | 129 | In Stock |
![]() ![]() |
50MG | 208 | In Stock |
![]() ![]() |
100MG | 332 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NamePlinabulin
-
NoteResearch use only, not for human use.
-
Brief DescriptionPlinabulin (NPI-2358) is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.
-
DescriptionPlinabulin (NPI-2358) is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.(In Vitro):Plinabulin (NPI-2358) (2-200 nM; 30 minutes; HUVECs cells) is a potent anti-tumor agent which is active in multidrug-resistant (MDR) tumor cell lines, and is able to rapidly induce tubulin depolymerization and monolayer permeability in HUVECs, with IC50 values of 18 nM for DU 145 cells; 13 nM for PC-3 cells; 14 nM for MDA-MB-231 cells; 18 nM for NCI-H292 cells; and 11 nM for Jurkat leukemia cells.(In Vivo):Plinabulin (0 mg/kg-15 mg/kg; intraperitoneal injection; female CDF1 and C3H/He mice) induces a time- and dose-dependent decrease in tumor perfusion. The KHT sarcoma is more sensitive than the C3H tumor to the anti-tumor effects of Plinabulin, while radiation response is enhanced in both models.
-
In VitroCell Viability Assay Cell Line:HUVECs cells Concentration:2 nM, 10 nM, 20 nM and 200 nM Incubation Time:30 minutes Result:Low concentrations (2 nM, 10 nM) rapidly induced tubulin depolymerization in HUVECs.
-
In VivoAnimal Model:Female CDF1 mice (10-14-week-old) with C3H mammary carcinoma; Female C3H/HeJ mice with KHT sarcoma cells (8-weeks-old)Dosage:0 mg/kg, 1.5 mg/kg, 2.5 mg/kg, 5 mg/kg, 7.5 mg/kg, 10 mg/kg, 12.5 mg/kg, 15 mg/kg;0.02 mL/g mouse body weight in CDF1 mice and 0.01 mL/g body weight for C3H/HeJ mice Administration:Intraperitoneal injection; 0 huor, 1 huor, 3 hours, 6 huors, 24 huors Result:Induced a time- and dose-dependent decrease in tumour perfusion. The KHT sarcoma was more sensitive than the C3H tumour to the anti-tumor, while radiation response was enhanced in both models.
-
SynonymsNPI-2358
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetMicrotubule/Tubulin
-
RecptorTubulin
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number714272-27-2
-
Formula Weight336.39
-
Molecular FormulaC19H20N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 54 mg/mL warmed (160.52 mM)
-
SMILESO=C(/C(NC/1=O)=C\C2=CC=CC=C2)NC1=C\C3=C(C(C)(C)C)NC=N3
-
Chemical Name(3E,6E)-3-benzylidene-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene)piperazine-2,5-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nicholson B, et al. anticancer Drugs, 2006, 17(1), 25-3
molnova catalog



related products
-
DJ101
A novel potent and metabolically stable tubulin inhibitor.
-
BNC105
BNC105 is a tubulin polymerization inhibitor. It has potent antiproliferative and tumor vascular disrupting properties.
-
Eribulin mesylate
Eribulin mesylate (B1939, E7389, ER-086526) is a macrocyclic ketone analogue of halichondrir B.